Robert S. Friedman, M.D., F.A.C.S. – Curriculum Vitae

The Eye Associates
941-923-2020 or Toll Free 1-866-865-2020

Education
Fellowship - Glaucoma
New York Eye and Ear Infirmary
New York, NY

Residency - Ophthalmology
Louisianna State University Eye Center
New Orleans, LA

Internship
Michael Reese Hospital and Medical Center
Chicago, IL

Doctorate of Medicine
Rosalind Franklin University of Medicine & Science/Chicago Medical School
Chicago, IL

Bachelor of Arts
Vanderbilt University
Nashville, TN

Professional Experience
-The Eye Associates, September 2010 to Present
-Kantor Eye Institute & Laser Center, April 2000 to September 2010
-Florida Eye Health, November 1999 to March 2000

Board Certifications
-Diplomate, American Board of Ophthalmology, 1994, 2005
-Diplomate, National Board of Medical Examiners, 1988

Professional Associations
-American Board of Ophthalmology
-American Academy of Ophthalmology
-National Board of Medical Examiners
-American Glaucoma Society
-American College of Surgeons
-Alpha Omega Alpha Honor Medical Society

Academic Appointments
-Clinical Assistant professor, Department of Clinical Sciences, Florida State University College of Medicine (2005 - Present)
-Adjunct Clinical Assistant Professor of Ophthalmology, Lake Erie College of Osteopathic Medicine (2006-Present)

Hospital and Surgery Center Affiliations
-The Eye Associates' Surgery Center, Bradenton, Florida
-Center for Advanced Eye Surgery, Sarasota, Florida
-Columbia Doctors Hospital, Sarasota, Florida
-Sarasota Memorial Hospital, Sarasota, Florida

Clinical Investigations
-March, 1994: Merck Protocol 047-00: A Parallel, Randomized, Double-Masked Study Comparing the 0.5% Timolol/2.0% MK-507 Combination Ophthalmic Solution to 0.5% Timolol Ophthalmic Solution or 2.0% MK-507 Ophthalmic Solution in Patients with Elevated Intraocular Pressure
-May, 1994: Insite Protocol C-93: A Three Month Study to Compare the Efficacy and Safety of 0.1% Betasite to 0.5% Betasite to 0.5% Betagan
-June, 1994: Merck Protocol 048-01: A One-Year, Parallel, Randomized, Double-Masked, Active-Controlled, Multiclinic Study Comparing the Corneal Safety of 2.0% MK-507 Ophthalmic Solution, 0.5% Timolol Ophthalmic Solution, and 0.5% Betaxolol Ophthalmic Solution in Patients with Elevated Intraocular Pressure with Ocular Hypertension or Glaucoma
-July, 1995: Alcon Laboratories Protocol C-95-48: A Three-Month, Multicenter, Triple-Masked, Primary Therapy Study of the Efficacy and Safety of BID and TID Dosed AL-4862 1.0% Ophthalmic Suspension Compared to TID Dosed Dorzolamide 2.0% and BID Dosed Timolol 0.5% in the Treatment of Patients with Primary Open-Angle Glaucoma or Ocular Hypertension
-Caronia RM, Liebmann JM, Friedman R, Cohen H, Ritch R.: Trabeculectomy at the inferior limbus. Arch Ophthalmol 114:4:387-391, 1996
-January, 1997: Allergan Protocol 192371-003-00: A Multicenter, Double-Masked, Randomized, Vehicle-Controlled, Parallel Group Study of the Safety and Efficacy of Cyclosporine 0.05% and 0.1% Ophthalmic Emulsions Used Twice Daily for Up to One Year in Patients with Moderate to Severe Keratoconjunctivitis Sicca
-October, 1997: Merck Protocol TRU414: A Parallel, Randomized, Double-Masked, Active Controlled, Multiclinic Study Comparing the Tolerability and Efficacy of 2.0% MK-507 Ophthalmic Solution and Orally Administered Acetazolamide in Patients with Ocular Hypertension or Glaucoma
-January, 1998: Alcon Laboratories Protocol C-97-72: A Six-Month, Triple-Masked, Parallel Group Therapy Study of the Safety and Efficacy of AL-6221 0.0015% and AL-6221 0.004% Compared to Timoptic 0.5% in Patients with Open-Angle Glaucoma or Ocular Hypertension
-March, 2001 Alcon Laboratories Protocol CM - 01 - 01: A Twelve Week Primary Therapy Study of the Safety and Efficiency of Travatan 0.004% in Patients Whose Intraocular Pressure is not Adequately Controlled on Timolol in Different Ethnic Populations
-July, 2001 Alcon Laboratories Protocol CM-01-06: A Four Week Therapy Study of the Efficiency of Travatan 0.004% in Patients Whose Intraocular Pressure is not Adequately Controlled or Who are Intolerant to Other Intraocular Pressure Lowing Medications


Print this Page